Cambridge, Massachusetts Thursday, October 17, 2024, 17:00 Hrs [IST] ...
Cullinan Therapeutics said the U.S. Food and Drug Administration approved its investigation new drug application for CLN-978, a potential treatment for lupus. The biopharmaceutical company said the ...
Cullinan Therapeutics has filed an investigational new drug application with the U.S. Food and Drug Administration (FDA) for CLN-978 for the treatment of systemic lupus erythematosus (SLE). Continue ...
Cullinan Therapeutics, Inc. (NASDAQ:CGEM – Get Free Report) has received a consensus recommendation of “Buy” from the six ratings firms that are covering the firm, MarketBeat Ratings reports.
Sept. 17, 2024 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM), a biopharmaceutical company focused on developing modality-agnostic targeted therapies, today received Human Research ...
BTIG analyst Julian Harrison reiterated a Buy rating on Outlook Therapeutics (OTLK – Research Report) today and set a price target of ...
CAMBRIDGE, Mass. - Cullinan Therapeutics, Inc. (NASDAQ: CGEM), a biopharmaceutical company, received approval from the U.S. Food and Drug Administration (FDA) to proceed with Phase 1 clinical ...
该公司还获得澳大利亚人类研究伦理委员会批准,开始针对治疗系统性红斑狼疮 (SLE)的药物CLN-978的全球一期试验。尽管Morgan Stanley将Cullinan的目标价下调至38美元,但仍维持了对公司的增持评级。
有趣的是，Cullinan的股票显示出显著的动力，InvestingPro提示强调过去一年的价格回报率为95.23%。这一大幅增长表明市场对该公司的产品线（包括最近获FDA批准的CLN-978项目）持乐观态度。此外，该公司的资产负债表上现金多于债务，这可能为其推进临床试验提供财务灵活性。
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
The overall quant rating is not an average of the factor grades listed. Instead, it gives greater weight to the metrics with the strongest predictive value.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback